Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended

Nautilus Biotechnology, Inc.

2022-Q3 EPS reported -$0.36

Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.
Net loss $14.1M vs $14.5M in Q3 2021; no revenue (pre-revenue biotech).
Cash, cash equivalents and investments $323.6M as of Sept 30, 2022.
Company advanced platform development including commercial instrument readiness.
Bylaws amended to update stockholder nomination procedures and conform to DGLC.

item 2.02 item 5.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nautilus Biotechnology, Inc. reported third quarter ended September 30, 2022 results: net income $14.1 million.

Period: third quarter ended September 30, 2022
Net income: $14.1 million
Result: reported results

Exact text from the filing

Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Nautilus Biotechnology, Inc.: Amended and restated bylaws to revise director nomination procedures, stockholder meeting provisions, remove lock-up provisions, update board and officer provisions, and make conforming ministerial changes (effective 2022-10-27).

Change: bylaw amendment
Effective: 2022-10-27

Exact text from the filing

On October 27, 2022, the Company’s board of directors, upon recommendation of the nominating and governance committee, amended and restated the Company’s amended and restated bylaws, effective immediately.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Nautilus Biotechnology, Inc. filing history →

Source: SEC EDGAR

accession 0001808805-22-000107

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.